Ocular Therapeutix OCUL Return on equity

Return on equity at other companies

Regeneron PharmaceuticalsREGN

14%-1.3pp

EyePoint, Inc.EYPT

-148.7%-13,871pp

KLR

Kalaris TherapeuticsKLRS

-66.6%—

Bausch + LombBLCO

-2.7%-0.7pp

HRO

HarrowHROW

-50%+17.5pp

Tarsus Pharmaceuticals, Inc.TARS

-13.7%-4.9pp

FAQ

What is Ocular Therapeutix's return on equity?

Ocular Therapeutix (OCUL) reported return on equity of -68.6% in Q1 2026.

How has Ocular Therapeutix's return on equity changed year-over-year?

Ocular Therapeutix's return on equity decreased by 19.9% year-over-year, from -57.2% to -68.6%.

What is the long-term trend for Ocular Therapeutix's return on equity?

Over 4 years (2021 to 2025), Ocular Therapeutix's return on equity has grown at a 61.9% compound annual growth rate (CAGR), from -8% to -54.9%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.